| Literature DB >> 25212890 |
Jooeun Bae1, Nikhil C Munshi2, Kenneth C Anderson2.
Abstract
Multiple myeloma (MM) is a B-cell malignancy characterized by the clonal proliferation of malignant plasma cells in the bone marrow and the development of osteolytic bone lesions. MM has emerged as a paradigm within the cancers for the success of drug discovery and translational medicine. This article discusses immunotherapy as an encouraging option for the goal of inducing effective and long-lasting therapeutic outcome. Divided into two distinct approaches, passive or active, immunotherapy, which targets tumor-associated antigens has shown promising results in multiple preclinical and clinical studies.Entities:
Keywords: Active-specific immunotherapy; Multiple myeloma; Passive-specific immunotherapy
Mesh:
Substances:
Year: 2014 PMID: 25212890 DOI: 10.1016/j.hoc.2014.07.002
Source DB: PubMed Journal: Hematol Oncol Clin North Am ISSN: 0889-8588 Impact factor: 3.722